Menicon announces distribution agreement with Optimed

Menicon Co., Ltd. has announced its agreement with Optimed Ltd. to become the exclusive distributor for Optimed's CAPTIV8 communication services and i-Vue content-driven digital signage software for North America. Earlier this year, Menicon obtained exclusive distribution rights for Optimed's products in Japan and Taiwan.

"First of all, I would like to say that it is great news to have Menicon as a strategic partner for the North American market," commented Dr. Trusit Dave, Director of Optimed. "This reinforces our shared vision that Optimed products have a strong potential to become the new standard for facilitating patient understanding and communication about the eye and eye health. We look forward to working closely with Menicon to support our combined effort."

CAPTIV8 is web-based 3D animation software that can be used by the eye-care practitioner chair-side to enhance communication with patients. The technology further enables patients to view the content on their computers, mobile devices and share it with family and friends.

i-Vue is a digital display system, normally located in the practice waiting room, that uses 3D animation to educate and inform patients about products and services. i-Vue allows users to easily and quickly modify playback content from any remote location, making it a convenient and ideal solution for multiple location practices.

"According to recent opinion polls, North American patients are especially concerned with their ability to communicate with their health care providers," explained Jonathan Jacobson, General Manager of Global Business Strategies & Operations of Menicon. "CAPTIV8 and i-Vue provide the eye-care practitioners with state-of-the-art and dynamic communication tools to explain complex information about eye health to patients. It uses the power of the internet and computer graphics to deliver meaningful content to consumers wanting to know more about their own eye health."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New insights on protein degraders open doors to treatment for 'undruggable' diseases